Synthesis of modified tripeptides and tetrapeptides as potential bisubstrate inhibitors of the epidermal growth factor receptor protein tyrosine kinase

被引:11
|
作者
Rosse, G
Sequin, U
Mett, H
Furet, P
Traxler, P
Fretz, H
机构
[1] UNIV BASEL, INST ORGAN CHEM, CH-4056 BASEL, SWITZERLAND
[2] CIBA GEIGY AG, DIV PHARMACEUT, CANC BONE METAB RES DEPT, CH-4002 BASEL, SWITZERLAND
关键词
D O I
10.1002/hlca.19970800304
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The synthesis of a series of bisubstrate inhibitors oi the epidermal growth factor receptor protein kinase (EGF-R PTK) consisting of small peptides linked covalently to adenosine via appropriate triphosphate substitutes is described. Boc-Glu(O'Bu)-Tyr-Leu-OBzl (5) and Ac-Glu(O'Bu)-Tyr-Leu-Arg(Pmc)-NH2 (8; Pmc = 2,2,5,7,8-pentamethylchroman-6-sulfonyl) ) were prepared by standard peptide chemistry, (Scheme I), then modified at the OH group of tyrosine either with adipic anhydride or with 4-(chlorosulfonyl)benzoic acid, 4-(chlorosulfonyl)2-hydroxybenzoic acid, or benzene-1,4-disulfonyldichloride (Scheme 2), and finally coupled with the 5'-OH group of 2',3'-O-isopropylideneadenosine (Scheme 3). In addition, N-6-[benzyloxy)carbonyl]-2',3'-O-isopropylidene- adenosine 5'-(hydrogenhexanedioate) (26), an ATP substitute, was coupled with the morpholide of 5 (Scheme 4). Removal of the protecting groups gave the bisubstrate analogs 23, 24, and 28. The compounds synthesized were tested as inhibitors of the EGF-R PTK. The most active bisubstrate-type inhibitor was 24, composed of the tripeptide sequence H-Glu-Tyr-Leu-OBzl, the 2-hydroxy-4-sulfonylbenzoyl moiety, and adenosine; ii showed an IC50 value of 33 mu M.
引用
收藏
页码:653 / 670
页数:18
相关论文
共 50 条
  • [2] Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor
    Liechti, C
    Séquin, U
    Bold, G
    Furet, P
    Meyer, T
    Traxler, P
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2004, 39 (01) : 11 - 26
  • [3] Epidermal growth factor receptor tyrosine kinase inhibitors
    M Ranson
    British Journal of Cancer, 2004, 90 : 2250 - 2255
  • [4] Epidermal growth factor receptor tyrosine kinase inhibitors
    Wakeling, AE
    CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (04) : 382 - 387
  • [5] Epidermal growth factor receptor tyrosine kinase inhibitors
    Ranson, M
    BRITISH JOURNAL OF CANCER, 2004, 90 (12) : 2250 - 2255
  • [6] Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives
    Kelloff, GJ
    Fay, JR
    Steele, VE
    Lubet, RA
    Boone, CW
    Crowell, JA
    Sigman, CC
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1996, 5 (08) : 657 - 666
  • [7] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Depression
    Pirl, William F.
    Solis, Jessica
    Greer, Joseph
    Sequist, Lecia
    Temel, Jennifer S.
    Lynch, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : E49 - E50
  • [8] Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Wozniak, Antoinette J.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : S1084 - S1085
  • [9] Synthesis and in vitro evaluation of epidermal growth factor receptor tyrosine kinase inhibitors.
    Lim, JK
    Riese, DJ
    Negash, K
    Hawkins, RA
    VanBrocklin, HF
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 20P - 21P
  • [10] Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
    Jimeno, Antonio
    Hidalgo, Manuel
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2006, 1766 (02): : 217 - 229